Drug Trial Radar · NCT07427394
Study to Evaluate the Safety and Tolerability of Camizestrant in Combination With Atirmociclib in Women With Advanced Breast Cancer
Last checked: Nov 19, 2026Latest source record: Sep 29, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
24
Planned (sponsor's estimate)
Start
May 6, 2026
Primary completion
Dec 28, 2027
Study completion Dec 28, 2027
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Feb 23, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Female only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study to investigate camizestrant in combination with atirmociclib in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer previously treated with a cyclin dependent kinase 4/6 (CDK4/6) inhibitor.
Conditions
- Advanced Breast Cancer
Interventions
CamizestrantDrug
Camizestrant will be administered orally.
AtirmociclibDrug
Atirmociclib will be administered orally.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events (AEs) and serious AEsTime frame: Up to Post-Treatment Follow up (Day 30 Post Dose)
Locations
6 sites in 2 countries. Site status is shown where the registry gives one.
Research Site
St Louis, Missouri · Recruiting
Research Site
East Providence, Rhode Island · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Cambridge, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Manchester, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.